Forget BMS. Pfizer should chase a Biogen buy, analyst suggests
admin 13th November 2017 Uncategorised 0One analyst isn’t sure Pfizer can afford to be behind in both immuno-oncology and Alzheimer’s. And while his peers have suggested bulking up in I-O to solve that issue, he has a different idea.
More: Forget BMS. Pfizer should chase a Biogen buy, analyst suggests
Source: fierce